Achieve Life Sciences Announces Participation at Key Healthcare Forum
Achieve Life Sciences Prepares for Jefferies Global Healthcare Conference
SEATTLE and VANCOUVER, British Columbia -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pioneering specialty pharmaceutical company, is gearing up for a major presentation at the Jefferies Global Healthcare Conference. This important event will take place from June 3–5 in the vibrant city of New York. With a dedicated focus on the development and commercialization of cytisinicline, Achieve aims to combat nicotine dependence and support smoking cessation efforts.
Presentation Details and Company Vision
Rick Stewart, the Chief Executive Officer of Achieve, is set to take the stage on June 4 at 5:30 PM EDT. This presentation will offer insights into the company’s ongoing advancements and the promising future of cytisinicline. Attendees will have the opportunity to access a live webcast of the event through the Investor Relations section of Achieve’s official website, ensuring that even those unable to attend in person can stay informed about developments.
Addressing the Smoking Epidemic
Achieve Life Sciences is committed to addressing the alarming global health issues stemming from smoking and nicotine dependence. Through innovative research, the company has successfully completed two Phase 3 studies focused on cytisinicline for smoking cessation, supplemented by additional studies targeting vaping cessation. The ongoing efforts aim to provide effective and accessible solutions for individuals looking to break free from nicotine addiction.
What is Cytisinicline?
Cytisinicline stands out as a plant-based alkaloid, specifically designed to interact with nicotinic acetylcholine receptors in the brain. This mechanism is believed to alleviate nicotine cravings and reduce the associated rewards tied to smoking and vaping. Importantly, cytisinicline has gained Breakthrough Therapy designation from the FDA, signifying its potential in filling a critical gap in nicotine addiction treatment—where currently no FDA-approved medications exist specifically for aiding e-cigarette cessation.
Company Commitment and Future Steps
With an ongoing open-label safety study already fully enrolled, Achieve is poised to submit a new drug application for cytisinicline in the near future. This submission will mark a significant achievement in the company's timeline, reflecting its dedication to bringing forth innovative therapeutic options for nicotine dependence.
Projected Impact on Public Health
The rising number of tobacco-related illnesses necessitates urgent intervention. As it stands, tobacco use accounts for over eight million deaths globally each year. Recognizing this alarming statistic, Achieve Life Sciences aims to be at the forefront of change with its cytisinicline treatment. By addressing the critical needs of millions looking to quit smoking or vaping, the company stands to make a substantial impact on public health.
Contact Achieve Life Sciences
For those seeking further details or wishing to connect directly, Achieve Life Sciences encourages all inquiries through their dedicated contact, Nicole Jones, at ir@achievelifesciences.com or via phone at 425-686-1510. This open line of communication reflects Achieve’s commitment to transparency and stakeholder engagement as they navigate their critical role in healthcare.
Frequently Asked Questions
What is the focus of Achieve Life Sciences?
Achieve Life Sciences focuses on the development of cytisinicline, aimed at treating nicotine dependence to support smoking and vaping cessation.
When will Achieve present at the Jefferies Global Healthcare Conference?
Rick Stewart, CEO, will present on June 4 at 5:30 PM EDT.
What is cytisinicline?
Cytisinicline is a plant-based compound designed to help reduce nicotine cravings and support cessation efforts for smoking and vaping.
What distinguishes cytisinicline from other nicotine aids?
Cytisinicline has been designated as a Breakthrough Therapy by the FDA, and it is specifically intended to aid in e-cigarette cessation, where no approved treatments currently exist.
How can I contact Achieve Life Sciences for more information?
You can reach out to Nicole Jones at Achieve Life Sciences via email at ir@achievelifesciences.com or call 425-686-1510.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.